By John Meyer, consultant in financial affairs – Eurasia Business News, June 2, 2025. Article no. 1535.

Sanofi has agreed to acquire Blueprint Medicines, a US-based biopharmaceutical company specializing in rare immunological diseases, for up to $9.5 billion on a fully diluted basis. The deal includes a cash offer of $129 per share, representing an equity value of approximately $9.1 billion, plus contingent value rights (CVRs) that could add up to $400 million based on future development and regulatory milestones for Blueprint’s drug BLU-808.

This acquisition expands Sanofi’s portfolio by adding Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (SM), a rare immunological disease characterized by abnormal mast cell accumulation and activation. The deal also brings in Blueprint’s early-stage immunology pipeline, including elenestinib, a next-generation medicine for SM, and BLU-808, a selective oral KIT inhibitor with potential to treat a broad range of immunological diseases.

Read also : Gold : Build Your Wealth and Freedom

Sanofi’s CEO Paul Hudson highlighted that the acquisition is a strategic step to enhance Sanofi’s rare and immunology portfolios, accelerating its transformation into a leading immunology company. The acquisition complements Sanofi’s recent early-stage medicine acquisitions and is expected to strengthen its presence among allergists, dermatologists, and immunologists.

The transaction is expected to close in the third quarter of 2025 and will be funded through a combination of cash reserves and new debt. Sanofi anticipates that the acquisition will contribute to improved financial performance starting in 2026, leveraging Blueprint’s innovative therapies to boost growth amid pharmaceutical competition.

Read also : Tax Management strategies for Digital Nomads

Our community already has nearly 150,000 readers!

Subscribe to our Telegram channel

Follow us on Telegram, Facebook and Twitter

© Copyright 2025 – Eurasia Business News. Article no. 1535.